AR012594A1 - Imidazoles sustituidos, composicion farmaceutica que los comprende, el uso de los mismos en la manufactura de un medicamento y procedimiento para supreparacion e intermediario - Google Patents
Imidazoles sustituidos, composicion farmaceutica que los comprende, el uso de los mismos en la manufactura de un medicamento y procedimiento para supreparacion e intermediarioInfo
- Publication number
- AR012594A1 AR012594A1 ARP980101886A ARP980101886A AR012594A1 AR 012594 A1 AR012594 A1 AR 012594A1 AR P980101886 A ARP980101886 A AR P980101886A AR P980101886 A ARP980101886 A AR P980101886A AR 012594 A1 AR012594 A1 AR 012594A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- substituted
- 5alkyl
- substituents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Abstract
Imidazoles sustituidos de la formula (I), en la cual R1 es fenilo, fenilo sustituido (donde los sustituyentes son seleccionados entre el grupo queconsiste en alquilo C1-5, halogeno, nitro trifluorometilo y nitrilo), o heteroarilo, donde elheteroarilo contiene de 5 a 6 átomos en el anillo; R2es fenilo, fenilo sustituido (donde los sustituyentes son seleccionados entre el grupo que consiste en alquilo C1-5, halogeno, nitro, triflurometilo ynitrilo), o heteroarilo, donde elheteroarilo contiene de 5 a 6 átmos en el anillo y está optativamente sustituido con alquilo C1-4; R3 es hidrogeno, SEM,alcoxicarbonilo C1-5, ariloxicarbonilo, arilalquiloxicarbonilo C1-5, arilalquilo C1-5, arilalquilo C1-5 sustituido(donde los sustituyentes ariloson independientemente seleccionados entre uno o más miembros del grupo que consiste en alquilo C1-5, halogeno, amino, alquilamino C1-5 y dialquilaminoC1-5), ftalimidoalquilo C1-5, aminoalquilo C1-5, diaminoalquiloC1-5, succinimidoalquilo C1-5, alquilcarbonilo C1-5, arilcarbonilo, alquilcarboniloC1-5 alquilo C1-5, ariloxicarbonilalquilo C1-5, heteroarilalquilo C1-5 , donde el heteroarilo contiene 5 o 6 átomos en el anillo; R4 es (A)-(CH2)q-X donde: Aesvinileno , etinileno o formula (II), donde R5 es seleccionado entre el grupo que consiste en hidrogeno, alquilo C1-5, fenilo y fenilalquilo C1-5; q es 0-9;X es seleccionado entre el grupo que consiste en hidrogeno, hidroxi, vinilo, vinilosustituido (dond e uno o más sustituyentes son seleccionados entre elgrupo que consiste en fluor, bromo, cloro y yodo), etinilo, etinilo sustituido (donde los sustituyentes son seleccionados entre uno o más del grupo queconsiste en fluor, bromo,cloro y yodo), alqui lo C1-5; alquilo C1-5 sustituido (donde los sustituyentes alquilo son seleccionados entre el grupo que consiste
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4425297P | 1997-04-24 | 1997-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR012594A1 true AR012594A1 (es) | 2000-11-08 |
Family
ID=21931339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980101886A AR012594A1 (es) | 1997-04-24 | 1998-04-23 | Imidazoles sustituidos, composicion farmaceutica que los comprende, el uso de los mismos en la manufactura de un medicamento y procedimiento para supreparacion e intermediario |
Country Status (24)
Country | Link |
---|---|
US (3) | US5965583A (es) |
EP (1) | EP1028954B1 (es) |
JP (1) | JP2001522357A (es) |
KR (1) | KR100568438B1 (es) |
CN (1) | CN1211381C (es) |
AR (1) | AR012594A1 (es) |
AT (1) | ATE244234T1 (es) |
AU (1) | AU7138298A (es) |
BR (1) | BR9808998A (es) |
CA (1) | CA2297176A1 (es) |
DE (1) | DE69816109T2 (es) |
DK (1) | DK1028954T3 (es) |
ES (1) | ES2202840T3 (es) |
HU (1) | HUP0002842A3 (es) |
IL (1) | IL132318A0 (es) |
NO (1) | NO318937B1 (es) |
NZ (1) | NZ500447A (es) |
PL (1) | PL191111B1 (es) |
PT (1) | PT1028954E (es) |
RU (1) | RU2222534C2 (es) |
TR (1) | TR199902622T2 (es) |
UA (1) | UA65572C2 (es) |
WO (1) | WO1998047892A1 (es) |
ZA (1) | ZA983451B (es) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916891A (en) | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
WO1998007425A1 (en) | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
EP1028954B1 (en) | 1997-04-24 | 2003-07-02 | Ortho-McNeil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory diseases |
JP2002504909A (ja) | 1997-06-13 | 2002-02-12 | スミスクライン・ビーチャム・コーポレイション | 新規な置換ピラゾールおよびピラゾリン化合物 |
US6610695B1 (en) | 1997-06-19 | 2003-08-26 | Smithkline Beecham Corporation | Aryloxy substituted pyrimidine imidazole compounds |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
US6562832B1 (en) | 1997-07-02 | 2003-05-13 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6489325B1 (en) | 1998-07-01 | 2002-12-03 | Smithkline Beecham Corporation | Substituted imidazole compounds |
AU8381098A (en) | 1997-07-02 | 1999-01-25 | Smithkline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
JP2001518507A (ja) | 1997-10-08 | 2001-10-16 | スミスクライン・ビーチャム・コーポレイション | 新規シクロアルケニル置換化合物 |
JPH11193281A (ja) * | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンa3受容体拮抗剤およびチアゾール化合物 |
US6335340B1 (en) | 1997-12-19 | 2002-01-01 | Smithkline Beecham Corporation | compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses |
BR9910621A (pt) | 1998-05-22 | 2001-01-30 | Smithkline Beecham Corp | Novos compostos de imidazol 2-alquil substituìdos |
US6858617B2 (en) | 1998-05-26 | 2005-02-22 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
CA2346665A1 (en) * | 1998-10-07 | 2000-04-13 | Smithkline Beecham Corporation | Novel treatment for stroke management |
ATE258055T1 (de) | 1998-11-04 | 2004-02-15 | Smithkline Beecham Corp | Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine |
AU3196900A (en) * | 1999-03-25 | 2000-10-16 | Welfide Corporation | Preventives/remedies for interstitial pneumonia and pulmonary fibrosis |
US6291457B1 (en) * | 1999-07-01 | 2001-09-18 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US6759410B1 (en) | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
WO2002032374A2 (en) * | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
DE60111417T2 (de) * | 2000-10-18 | 2006-03-16 | Ortho-Mcneil Pharmaceutical, Inc. | Substituierte imidazole, die sich für die behandlung entzündlicher krankheiten eignen |
EP1508569A3 (en) * | 2001-03-26 | 2005-09-14 | Ortho-McNeil Pharmaceutical, Inc. | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof |
CN1800178A (zh) * | 2001-03-26 | 2006-07-12 | 奥索-麦克尼尔药品公司 | 制备四取代咪唑衍生物及其新型晶体结构的方法 |
GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
PL222211B1 (pl) | 2001-06-26 | 2016-07-29 | Amgen Fremont Inc | Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza |
AU2002324625B2 (en) * | 2001-08-07 | 2008-05-08 | Immunex Corporation | Interleukin-1 receptors in the treatment of diseases |
KR20020009532A (ko) * | 2001-11-13 | 2002-02-01 | (주)쎌믹스 | 류코트리엔 합성 억제용 조성물 |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
HRP20020453A2 (en) | 2002-05-23 | 2003-12-31 | Pliva D D | 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof |
EP1534282B1 (en) | 2002-07-09 | 2006-12-27 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
ES2497116T3 (es) * | 2002-08-19 | 2014-09-22 | Lorus Therapeutics Inc. | Imidazoles 2,4,5-trisustituidos y su uso como agentes antimicrobianos |
UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
NZ593428A (en) | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
JP4617299B2 (ja) * | 2003-03-03 | 2011-01-19 | アレイ バイオファーマ、インコーポレイテッド | p38阻害剤及びその使用法 |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7553827B2 (en) * | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US7429378B2 (en) * | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US20040229878A1 (en) * | 2003-05-13 | 2004-11-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of P38 kinase |
US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
EP1631145A4 (en) * | 2003-06-06 | 2009-12-23 | Univ Pennsylvania | P38 KINASEHEMMER COMPOSITION AND METHOD FOR THEIR USE |
US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
AU2004289539C1 (en) * | 2003-11-14 | 2012-06-07 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
WO2005063716A1 (en) * | 2003-12-22 | 2005-07-14 | Janssen Pharmaceutica, N.V. | Imidazoles and their use cck-1 receptor modulators |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
US20080119498A1 (en) * | 2004-12-06 | 2008-05-22 | Masatomo Kato | Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active Ingredient |
US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
US8148392B2 (en) * | 2005-05-25 | 2012-04-03 | Lorus Therapeutics Inc. | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer |
JP2009500297A (ja) | 2005-06-08 | 2009-01-08 | セントカー・インコーポレーテツド | 眼の変性についての細胞療法 |
JP5131990B2 (ja) * | 2006-01-31 | 2013-01-30 | アレイ バイオファーマ、インコーポレイテッド | キナーゼ阻害剤およびその使用方法 |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
RU2473685C2 (ru) | 2007-07-31 | 2013-01-27 | Лайфскен, Инк. | Дифференцировка человеческих эмбриональных стволовых клеток |
RU2473684C2 (ru) | 2007-11-27 | 2013-01-27 | Лайфскен, Инк. | Дифференцировка человеческих эмбриональных стволовых клеток |
US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
KR102026622B1 (ko) | 2008-02-21 | 2019-09-30 | 얀센 바이오테크 인코포레이티드 | 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물 |
EP2111861A1 (en) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
US8623648B2 (en) * | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
WO2010002846A1 (en) | 2008-06-30 | 2010-01-07 | Centocor Ortho Biotech Inc. | Differentiation of pluripotent stem cells |
CN102272291B (zh) | 2008-10-31 | 2018-01-16 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌谱系的分化 |
EP2350265B1 (en) | 2008-10-31 | 2019-04-17 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
EP2366022B1 (en) | 2008-11-20 | 2016-04-27 | Janssen Biotech, Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
MX356756B (es) | 2008-11-20 | 2018-06-11 | Centocor Ortho Biotech Inc | Células madre pluripotentes en microportadores. |
US8334287B2 (en) * | 2009-07-17 | 2012-12-18 | Hoffmann-La Roche Inc. | Imidazoles |
RU2540016C2 (ru) | 2009-07-20 | 2015-01-27 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека |
MX340952B (es) | 2009-07-20 | 2016-07-29 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas. |
KR102058901B1 (ko) | 2009-07-20 | 2019-12-24 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
US9150833B2 (en) | 2009-12-23 | 2015-10-06 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
KR101841271B1 (ko) | 2009-12-23 | 2018-03-22 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
JP6013196B2 (ja) | 2010-03-01 | 2016-10-25 | ヤンセン バイオテツク,インコーポレーテツド | 多能性幹細胞から誘導した細胞を精製するための方法 |
EP2569419B1 (en) | 2010-05-12 | 2019-03-20 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
CA2809305C (en) | 2010-08-31 | 2019-06-11 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
SG10201506855RA (en) | 2010-08-31 | 2015-10-29 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
BR112013004514A2 (pt) | 2010-08-31 | 2016-06-07 | Janssen Biotech Inc | diferenciação das células-tronco embrionárias humanas |
KR102203056B1 (ko) | 2011-12-22 | 2021-01-14 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화 |
ES2897740T3 (es) | 2011-12-28 | 2022-03-02 | Kyoto Prefectural Public Univ Corp | Normalización del cultivo de células endoteliales de la córnea |
WO2013134378A1 (en) | 2012-03-07 | 2013-09-12 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
CN108103006A (zh) | 2012-06-08 | 2018-06-01 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌细胞的分化 |
KR101942769B1 (ko) | 2012-12-31 | 2019-01-28 | 얀센 바이오테크 인코포레이티드 | Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화 |
RU2658488C2 (ru) | 2012-12-31 | 2018-06-21 | Янссен Байотек, Инк. | Способ получения клеток, экспрессирующих маркеры, характерные для панкреатических эндокринных клеток |
EP4039798A1 (en) | 2012-12-31 | 2022-08-10 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
JP2016516082A (ja) | 2013-03-20 | 2016-06-02 | アプトース バイオサイエンシーズ, インコーポレイテッド | 2−置換イミダゾ[4,5−d]フェナントロリン誘導体及び癌の治療におけるそれらの使用 |
DK3052102T3 (da) | 2013-10-04 | 2020-03-09 | Aptose Biosciences Inc | Sammensætninger til behandling af cancere |
EP3069732B1 (en) | 2013-11-14 | 2023-07-12 | The Doshisha | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage |
DK3143127T3 (da) | 2014-05-16 | 2021-09-13 | Janssen Biotech Inc | Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller |
BR112016026556A8 (pt) | 2014-05-16 | 2021-07-06 | Atriva Therapeutics Gmbh | inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção |
AU2015309687B2 (en) | 2014-08-25 | 2020-08-13 | EverBrilliant Pharma Pty Ltd | MAPK inhibitors |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
LT3691620T (lt) | 2017-10-05 | 2022-09-26 | Fulcrum Therapeutics, Inc. | P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
KR20200096914A (ko) | 2017-10-30 | 2020-08-14 | 압토스 바이오사이언시스 인코포레이티드 | 암 치료용 아릴 이미다졸 |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
MX2023000919A (es) | 2020-07-20 | 2023-04-19 | Annexon Inc | Inhibidores de factores del complemento y usos de los mismos. |
WO2023280911A1 (en) | 2021-07-06 | 2023-01-12 | Westfälische Wilhelms-Universität Münster | P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0004648B1 (de) * | 1978-04-11 | 1982-08-25 | Ciba-Geigy Ag | Neue Mercaptoimidazolderivate, Verfahren zu deren Herstellung, Mercaptoimidazolderivate zur Behandlung entzündlicher Erkrankungen und diese enthaltende pharmazeutische Präparate |
GR75287B (es) * | 1980-07-25 | 1984-07-13 | Ciba Geigy Ag | |
US4503065A (en) * | 1982-08-03 | 1985-03-05 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl 1-2-halo imidazoles |
US5633377A (en) * | 1990-12-28 | 1997-05-27 | Neurogen Corporation | 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands |
MX9300141A (es) * | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
EP1028954B1 (en) | 1997-04-24 | 2003-07-02 | Ortho-McNeil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory diseases |
-
1998
- 1998-04-17 EP EP98918463A patent/EP1028954B1/en not_active Expired - Lifetime
- 1998-04-17 RU RU99122164/04A patent/RU2222534C2/ru not_active IP Right Cessation
- 1998-04-17 JP JP54623198A patent/JP2001522357A/ja not_active Withdrawn
- 1998-04-17 CN CNB988045230A patent/CN1211381C/zh not_active Expired - Fee Related
- 1998-04-17 UA UA99105811A patent/UA65572C2/uk unknown
- 1998-04-17 TR TR1999/02622T patent/TR199902622T2/xx unknown
- 1998-04-17 HU HU0002842A patent/HUP0002842A3/hu unknown
- 1998-04-17 KR KR1019997009785A patent/KR100568438B1/ko not_active IP Right Cessation
- 1998-04-17 IL IL13231898A patent/IL132318A0/xx not_active IP Right Cessation
- 1998-04-17 PL PL336758A patent/PL191111B1/pl not_active IP Right Cessation
- 1998-04-17 PT PT98918463T patent/PT1028954E/pt unknown
- 1998-04-17 AU AU71382/98A patent/AU7138298A/en not_active Abandoned
- 1998-04-17 AT AT98918463T patent/ATE244234T1/de not_active IP Right Cessation
- 1998-04-17 WO PCT/US1998/007910 patent/WO1998047892A1/en not_active Application Discontinuation
- 1998-04-17 ES ES98918463T patent/ES2202840T3/es not_active Expired - Lifetime
- 1998-04-17 DE DE69816109T patent/DE69816109T2/de not_active Expired - Fee Related
- 1998-04-17 DK DK98918463T patent/DK1028954T3/da active
- 1998-04-17 US US09/062,304 patent/US5965583A/en not_active Expired - Lifetime
- 1998-04-17 BR BR9808998-6A patent/BR9808998A/pt not_active Application Discontinuation
- 1998-04-17 CA CA002297176A patent/CA2297176A1/en not_active Abandoned
- 1998-04-17 NZ NZ500447A patent/NZ500447A/en unknown
- 1998-04-23 ZA ZA9803451A patent/ZA983451B/xx unknown
- 1998-04-23 AR ARP980101886A patent/AR012594A1/es not_active Application Discontinuation
-
1999
- 1999-04-20 US US09/295,156 patent/US6214830B1/en not_active Expired - Lifetime
- 1999-10-19 NO NO19995095A patent/NO318937B1/no unknown
-
2000
- 2000-11-03 US US09/705,508 patent/US6521655B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69816109T2 (de) | 2004-04-22 |
TR199902622T2 (xx) | 2000-05-22 |
UA65572C2 (en) | 2004-04-15 |
US6521655B1 (en) | 2003-02-18 |
NO995095D0 (no) | 1999-10-19 |
NO318937B1 (no) | 2005-05-30 |
US6214830B1 (en) | 2001-04-10 |
DE69816109D1 (de) | 2003-08-07 |
BR9808998A (pt) | 2000-08-08 |
NZ500447A (en) | 2001-09-28 |
WO1998047892A1 (en) | 1998-10-29 |
KR20010020204A (ko) | 2001-03-15 |
CA2297176A1 (en) | 1998-10-29 |
ES2202840T3 (es) | 2004-04-01 |
NO995095L (no) | 1999-12-09 |
CN1253558A (zh) | 2000-05-17 |
US5965583A (en) | 1999-10-12 |
IL132318A0 (en) | 2001-03-19 |
KR100568438B1 (ko) | 2006-04-07 |
HUP0002842A2 (hu) | 2001-06-28 |
CN1211381C (zh) | 2005-07-20 |
AU7138298A (en) | 1998-11-13 |
PT1028954E (pt) | 2003-11-28 |
ZA983451B (en) | 1999-10-25 |
ATE244234T1 (de) | 2003-07-15 |
EP1028954A1 (en) | 2000-08-23 |
JP2001522357A (ja) | 2001-11-13 |
DK1028954T3 (da) | 2003-10-27 |
PL191111B1 (pl) | 2006-03-31 |
RU2222534C2 (ru) | 2004-01-27 |
PL336758A1 (en) | 2000-07-17 |
EP1028954B1 (en) | 2003-07-02 |
HUP0002842A3 (en) | 2002-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR012594A1 (es) | Imidazoles sustituidos, composicion farmaceutica que los comprende, el uso de los mismos en la manufactura de un medicamento y procedimiento para supreparacion e intermediario | |
AR054524A1 (es) | Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato | |
ES2062320T3 (es) | Fungicidas. | |
AR063294A1 (es) | Composiciones de carbamatos de fenilalquilo | |
CO4970728A1 (es) | 2-aminopiridinas que contienen sustituyentes de anillos condensados | |
ECSP077290A (es) | Derivados de isoxazolina y su uso como herbicidas | |
AR017967A1 (es) | Compuestos azapoliciclicos condensados con arilo, composiciones farmaceuticas de los mismos, su uso en la preparacion de medicamentos. | |
PE31691A1 (es) | Procedimiento para la preparacion de nuevos compuestos fungicidas | |
ES2189251T3 (es) | Procedimiento de preparacion de diarilpiridinas utiles como inhibidores de cox-2'. | |
AR048213A1 (es) | 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol | |
AR035756A1 (es) | Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos | |
AR054551A1 (es) | Metodos para la neuroproteccion | |
AR033426A1 (es) | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento | |
ES2052521T3 (es) | Derivados de aminoimidazoquinolina. | |
EA200600979A1 (ru) | Замещённые арилпиразолы в качестве противопаразитарных средств | |
AR033427A1 (es) | Uso de compuestos carbamatos en el tratamiento del dolor | |
AR005672A1 (es) | Derivados de la distamicina, proceso para prepararlos, y su utilizacion como agentes antitumorales y antivirales. | |
PA8514501A1 (es) | Compuestos de eter difenilico utiles en terapia | |
AR027399A1 (es) | Compuestos heterociclicos utiles como inhibidores de la fosfodiesterasa iv, composiciones formuladas con dichos compuestos y uso de dichos compuestos parapreparar dichas composiciones | |
YU124291A (sh) | N-i n'-supstituisani sulfonilkarbamidi i postupci za njihovo dobijanje | |
AR012924A1 (es) | Derivados de tiazolidindiona, oxazolidindiona y oxadiazolidindiona, proceso para su preparacion, composiciones y formulaciones farmaceuticas, usode dichos compuestos para la fabricacion de formulaciones y metodo de tratamiento | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
PE20030592A1 (es) | Antagonista de nk1 | |
AR037098A1 (es) | Proceso para preparar un compuesto intermediario derivado de halo alquil sulfona y compuestos intermediarios que se usan en dicho proceso | |
AR004484A1 (es) | Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |